EU clears Ipsen’s Ojemda for BRAF-altered pediatric glioma
Bottom line
Ipsen said the European Commission has granted conditional marketing authorization for Ojemda (tovorafenib) as monotherapy for children 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation, after at least one prior systemic therapy. The decision, announced April 22, 2026, follows a positive CHMP opinion issued on February 26, 2026, and applies across the 27 EU member states plus Iceland, Liechtenstein, and Norway. Ipsen is commercializing the drug outside the U.S. under its 2024 licensing deal with Day One Biopharmaceuticals. (ipsen.com)
Why it matters: While this is a human oncology approval, it signals continued momentum for biomarker-driven pediatric cancer treatment and reinforces how molecular diagnostics are shaping therapy selection in rare tumors. For veterinary professionals, the broader takeaway is the growing regulatory and commercial validation of targeted therapies tied to specific genomic alterations, rather than tumor location alone. The approval was based on the phase 2 FIREFLY-1 study, which evaluated tovorafenib in previously treated children and young adults with RAF-altered tumors; published and regulatory summaries describe meaningful response rates and durable disease control in this hard-to-treat setting. (ipsen.com)
What to watch: Watch for EU launch sequencing, country-level reimbursement decisions, and confirmatory follow-up data required under the drug’s conditional approval pathway. (ema.europa.eu)
Ipsen has won a new European approval for Ojemda (tovorafenib), with the European Commission granting conditional marketing authorization for the targeted therapy in relapsed or refractory pediatric low-grade glioma with qualifying BRAF alterations. The April 22, 2026 decision covers patients 6 months of age and older whose disease has progressed after one or more prior systemic therapies, and it extends across all EU member states as well as Iceland, Liechtenstein, and Norway. Ipsen is positioning Ojemda as the first targeted therapy in Europe for this setting across both BRAF fusions or rearrangements and BRAF V600 mutations. (ipsen.com)
The approval builds on a regulatory path that moved quickly this year. EMA’s CHMP adopted a positive opinion on February 26, 2026, recommending a conditional authorization, which is typically used when a medicine addresses an unmet need but confirmatory evidence is still being gathered. Ojemda already reached the U.S. market earlier, after FDA accelerated approval on April 23, 2024, giving the product an established foothold before Ipsen’s EU push. Ipsen gained ex-U.S. commercialization rights through a July 25, 2024 agreement with Day One Biopharmaceuticals, while Day One retained U.S. rights. (ema.europa.eu)
The European decision rests on FIREFLY-1, an ongoing phase 2, open-label, multicenter study in children, adolescents, and young adults with relapsed or refractory RAF-altered pediatric low-grade glioma or advanced solid tumors. Ipsen said the EU filing was supported by data from 137 treated patients in the broader study population, while EMA’s public summary highlighted efficacy data from 77 pediatric low-grade glioma patients with BRAF-altered disease whose tumors had progressed after prior systemic treatment. Published FIREFLY-1 results in Nature Medicine reported a 67% overall response rate by independent review using RANO-HGG criteria, with a median duration of response of 16.6 months. U.S. labeling based on RAPNO assessment reports a 53% overall response rate and an 18-month median duration of response, underscoring that response estimates vary by assessment method, but still point in the same direction: durable activity in a population with limited options. (ipsen.com)
Ipsen’s messaging around the approval has emphasized both unmet need and market differentiation. In its announcement, the company said more than 800 children are diagnosed each year in the EU with BRAF-altered pediatric low-grade glioma. The company also framed Ojemda as a therapy developed around the biology of the disease, rather than a repurposed general chemotherapy approach. That positioning matters because pediatric low-grade glioma is often slow growing but can still leave children with major long-term neurologic, visual, motor, and developmental burdens. (biospace.com)
Independent expert reaction in the immediate coverage window appears limited so far, but the broader oncology community has already treated tovorafenib as an important advance. NCI described the FDA approval in 2024 as notable because low-grade gliomas are the most common brain tumors in children and because BRAF-altered disease had lacked comparable targeted options, especially for fusion-driven tumors. Coverage of updated FIREFLY-1 data presented in late 2025 also suggested the field is increasingly viewing tovorafenib as a potential standard-setting option in relapsed or refractory disease, particularly given the durability of responses and the possibility of maintaining control during treatment breaks. (cancer.gov)
Why it matters: For veterinary professionals, this isn’t a practice-changing animal health development, but it is a useful signal about where oncology is heading. The Ojemda decision reflects a familiar pattern that increasingly crosses species lines: genomic profiling identifies a driver alteration, regulators accept smaller but biomarker-enriched datasets in rare disease, and companies build treatment strategies around molecular subsets rather than broad tumor categories. That has implications for comparative oncology, for expectations around precision medicine in referral settings, and for how pet parents may increasingly understand cancer care through a biomarker-first lens shaped by human medicine. The case also shows how conditional or accelerated pathways can bring targeted agents to patients earlier, while leaving post-approval evidence generation to sort out longer-term benefit and safety. (ema.europa.eu)
What to watch: The next milestones are practical, not just regulatory: Ipsen’s country-by-country pricing and reimbursement negotiations in Europe, publication or presentation of longer-term FIREFLY-1 follow-up, and any confirmatory data that convert conditional authorization into a standard approval. It will also be worth watching whether broader use of BRAF-directed treatment in pediatric neuro-oncology increases pressure for earlier molecular testing at diagnosis and relapse. (ema.europa.eu)